EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Michael E Wechsler, Guy Brusselle iD, J Christian Virchow iD, Arnaud Bourdin iD, Konstantinos Kostikas iD, Jean-Pierre Llanos iD, Stephanie L Roseti, Christopher S Ambrose, Gillian Hunter, David J Jackson, Mario Castro, Njira Lugogo und 3 weitere

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00316-2024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Michael E Wechsler und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents, Remission Induction. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by AstraZeneca and Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In asthma, clinical response is characterised by disease improvement with treatment, whereas clinical remission is characterised by long-term disease stabilisation with or without ongoing treatment. The proportions of patients receiving tezepelumab who responded to treatment and who achieved on-treatment clinical remission were assessed in the NAVIGATOR (ClinicalTrials.gov identifier NCT03347279 ) and DESTINATION (ClinicalTrials.gov identifier NCT03706079 ) studies of severe, uncontrolled asthma.

Methods

NAVIGATOR and DESTINATION were phase 3, randomised, double-blind, placebo-controlled studies; DESTINATION was an extension of NAVIGATOR. Complete clinical response was defined as achieving all of the following: ≥50% reduction in exacerbations versus the previous year, improvements in pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV 1 ) of ≥100 mL or ≥5%, improvements in Asthma Control Questionnaire (ACQ)-6 score of ≥0.5 and physician's assessment of asthma improvement. On-treatment clinical remission was defined as an ACQ-6 total score ≤1.5, stable lung function (pre-BD FEV 1 >95% of baseline) and no exacerbations or use of oral corticosteroids during the time periods assessed.

Results

Higher proportions of tezepelumab than placebo recipients achieved complete clinical response over weeks 0–52 (46% versus 24%; OR 2.83, 95% CI 2.10–3.82) and on-treatment clinical remission over weeks 0–52 (28.5% versus 21.9%; OR 1.44, 95% CI 0.95–2.19) and weeks >52–104 (33.5% versus 26.7%; OR 1.44, 95% CI 0.97–2.14). Tezepelumab recipients who achieved on-treatment clinical remission versus complete clinical response at week 52 had better preserved lung function and lower inflammatory biomarker levels at baseline, and fewer exacerbations in the 12 months before the study.

Conclusions

Among patients with severe, uncontrolled asthma, tezepelumab treatment was associated with an increased likelihood of achieving complete clinical response and on-treatment clinical remission compared with placebo. Both are clinically important outcomes, but may be driven by different patient characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsRemission InductionHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultTreatment OutcomeForced Expiratory VolumeSeverity of Illness IndexAged

Substanzen

Antibodies, Monoclonal, HumanizedtezepelumabAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Department of Pneumology and Department of Intensive Care Medicine, University of Rostock, Rostock, Germany.
  • PhyMedExp, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.
  • Respiratory Medicine Department, University of Ioannina, Ioannina, Greece.
  • Global Medical Affairs, Amgen, Thousand Oaks, CA, USA.

ORCID-Profile: Guy Brusselle, J Christian Virchow, Arnaud Bourdin, Konstantinos Kostikas, Jean-Pierre Llanos

Förderung

  • This study was funded by AstraZeneca and Amgen Inc.

Zitieren

APA

Wechsler, M. E., Brusselle, G., Virchow, J. C., Bourdin, A., Kostikas, K., Llanos, J. P., Roseti, S. L., Ambrose, C. S., Hunter, G., Jackson, D. J., Castro, M., Lugogo, N., Pavord, I. D., Martin, N., & Brightling, C. E. (2024). Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. European Respiratory Journal. https://doi.org/10.1183/13993003.00316-2024

Vancouver

Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. European Respiratory Journal. 2024. doi:10.1183/13993003.00316-2024

BibTeX
@article{Wechsler2024,
  author = {Wechsler, Michael E and Brusselle, Guy and Virchow, J Christian and Bourdin, Arnaud and Kostikas, Konstantinos and Llanos, Jean-Pierre and Roseti, Stephanie L and Ambrose, Christopher S and Hunter, Gillian and Jackson, David J and Castro, Mario and Lugogo, Njira and Pavord, Ian D and Martin, Neil and Brightling, Christopher E},
  title = {Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00316-2024}
}
Kostenlos starten →